Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Chemical Compound Review:

Neoquin 5-(aziridin-1-yl)-3- (hydroxymethyl)-2-[(E)...

Synonyms: Apaziquone, EOquin, Apaziquonum, EO-9, AC1NXQZI, ...

Puri, R. et al., Vainchtein, L.D. et al., van der Heijden, A.G. et al.

Vainchtein, Rosing, Mirejovsky, Huynh, Lenaz, Hillebrand, Schellens, Beijnen,

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Apaziquone

We determined the dose of apaziquone that can be safely administered intravesically and explored its activity for superficial bladder transitional cell carcinoma [1].
Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response [2].

High impact information on Apaziquone

MATERIALS AND METHODS: Six patients with multifocal, Ta/T1 and G1/G2 transitional cell carcinoma of the bladder received escalating doses of apaziquone formulated as EOquintrade mark (0.5 mg/40 ml up to 16 mg/40 ml) weekly for 6 weeks [1].

Analytical, diagnostic and therapeutic context of Apaziquone

CONCLUSIONS: Intravesical administration of 4 mg/40 ml apaziquone was well tolerated and had ablative activity against superficial bladder cancer marker lesions [1].
Quantitative analysis of EO9 (apaziquone) and its metabolite EO5a in human plasma by high-performance liquid chromatography under basic conditions coupled to electrospray tandem mass spectrometry [3].

References

Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer. Puri, R., Palit, V., Loadman, P.M., Flannigan, M., Shah, T., Choudry, G.A., Basu, S., Double, J.A., Lenaz, G., Chawla, S., Beer, M., Van Kalken, C., de Boer, R., Beijnen, J.H., Twelves, C.J., Phillips, R.M. J. Urol. (2006) [Pubmed]
Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response. van der Heijden, A.G., Moonen, P.M., Cornel, E.B., Vergunst, H., de Reijke, T.M., van Boven, E., Barten, E.J., Puri, R., van Kalken, C.K., Witjes, J.A. J. Urol. (2006) [Pubmed]
Quantitative analysis of EO9 (apaziquone) and its metabolite EO5a in human plasma by high-performance liquid chromatography under basic conditions coupled to electrospray tandem mass spectrometry. Vainchtein, L.D., Rosing, H., Mirejovsky, D., Huynh, V., Lenaz, L., Hillebrand, M.J., Schellens, J.H., Beijnen, J.H. Journal of mass spectrometry : JMS. (2006) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use

[search][advanced]